On July 24, AKESO fell 3.11% in regular trading, trading at 99.55 HKD/share, with turnover of 452 million HKD.

The decline comes after two consecutive sessions of strong gains, with the stock having risen approximately 7% on July 22 and over 4% on July 23, triggering profit-taking pressure. The broader biotechnology sector also traded weak, with Remegen down 3.84%, 3SBio down 2.11%, SKB Bio down 0.96%, and Innovent Bio down 0.16%, creating synchronized downward pressure. Only BeiGene bucked the trend, rising 3.41%.

On the fundamental side, overseas partner Summit Therapeutics recently updated overall survival data from the global Phase III HARMONi study of ivonescimab, showing OS hazard ratio improved to 0.76 for Western patients, confirming cross-ethnic efficacy consistency. The data has been submitted to the FDA to support BLA review, and the mid-to-long-term global registration value remains unchanged.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)